产品
编 号：F761445
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 918127-53-4
产品详情
生物活性：
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
体内研究：
Tigatuzumab (3mg /kg；静脉注射；每周一次，共 4 周) 有效抑制人胰腺癌 MIA PaCa-2-RFP 原位小鼠模型的肿瘤生长。Animal Model:Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection
Dosage:3 mg/kg
Administration:Intravenous injection; 3 mg/kg weekly for 4 weeks
Result:Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
体外研究：
Tigatuzumab 对 MIA PaCa-2 细胞和 BxPC-3 细胞敏感，IC50 值分别为 2.95 和 8.21 μg/mL。Tigatuzumab (3-8 μg/mL; 5 h) 诱导癌细胞凋亡。
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
体内研究：
Tigatuzumab (3mg /kg；静脉注射；每周一次，共 4 周) 有效抑制人胰腺癌 MIA PaCa-2-RFP 原位小鼠模型的肿瘤生长。Animal Model:Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection
Dosage:3 mg/kg
Administration:Intravenous injection; 3 mg/kg weekly for 4 weeks
Result:Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
体外研究：
Tigatuzumab 对 MIA PaCa-2 细胞和 BxPC-3 细胞敏感，IC50 值分别为 2.95 和 8.21 μg/mL。Tigatuzumab (3-8 μg/mL; 5 h) 诱导癌细胞凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备